ADC Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-240.05	-157.13	-230.03	-246.29	-116.48	-123.1
Depreciation & Amortization	3.27	2.39	2.63	1.97	1.65	0.74
Share-Based Compensation	13.5	49.32	60.48	37.59	1.12	0.47
Other Operating Activities	104.61	-32.89	-60.58	38.69	-8.72	-0.34
Operating Cash Flow	-118.69	-138.31	-227.5	-168.05	-122.44	-122.23
Capital Expenditures	-3.22	-0.69	-3.43	-0.8	-0.36	-0.94
Other Investing Activities	-	-	-3.24	-2.03	-1.89	-1.56
Investing Cash Flow	-3.22	-0.69	-6.67	-2.83	-2.25	-2.51
Share Issuance / Repurchase	0.77	6.13	0.78	433.21	101.51	-0.02
Debt Issued / Paid	0	-2.71	48.61	61.75	-1	0
Other Financing Activities	73.1	-4.32	218	-	-	-
Financing Cash Flow	73.88	-0.9	267.39	494.97	100.51	-0.02
Exchange Rate Effect	0.18	-0.21	0.01	0.24	0.06	-0.05
Net Cash Flow	-48.03	-139.9	27.34	323.41	-23.32	-123.89
Free Cash Flow	-121.9	-139	-230.93	-168.85	-122.8	-123.17
Free Cash Flow Margin	-175.25%	-66.22%	-680.85%	-	-5247.74%	-10804.56%
Free Cash Flow Per Share	-1.49	-1.78	-3.01	-2.38	-1.84	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).